Advancing risk assessment for emerging infectious diseases for blood and blood products: Proceedings of a public workshop

Transfusion

Volumn 53, Issue 2, 2013, Pages 455-463

  Gallagher, Lou M ^a   Ganz, Peter R ^a   Yang, Hong ^a   Kessler, Debra A ^a   O'Brien, Sheila F ^a   Custer, Brian S ^a   Busch, Michael P ^a   Dodd, Roger Y ^a   Stramer, Susan L ^a   Walderhaug, Mark O ^a   Forshee, Richard A ^a   Williams, Alan E ^a   Epstein, Jay S ^a   Anderson, Steven A ^a  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD BANK; BLOOD DONOR; BLOOD SAFETY; BLOOD TRANSFUSION; CANADA; CHAGAS DISEASE; CONFERENCE PAPER; CREUTZFELDT JAKOB DISEASE; DENGUE; DISEASE TRANSMISSION; HUMAN; INFECTION; INFECTION RISK; PIROPLASMOSIS; PREVALENCE; QUESTIONNAIRE; RISK ASSESSMENT; SEROPREVALENCE; TRANSFUSION TRANSMITTED DISEASE;

ANIMALS; BLOOD BANKS; BLOOD COMPONENT TRANSFUSION; BLOOD SAFETY; CANADA; COMMUNICABLE DISEASES, EMERGING; CONGRESSES AS TOPIC; DONOR SELECTION; EDUCATION; HUMANS; PUBLIC SECTOR; QUESTIONNAIRES; RED CROSS; RISK ASSESSMENT; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84873481119     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2012.03808.x     Document Type: Conference Paper

References (47)

1. Petersen LR, Tomashek KM, Biggerstaff BJ,. Estimated prevalence of dengue viremia in Puerto Rican blood donations, 1995 through 2010. Transfusion 2012; 52: 1647-51.
2. Young C, Losikoff P, Chawla A, Glasser L, Forman E,. Transfusion-acquired Trypanosoma cruzi infection. Transfusion 2007; 47: 540-4.
3. Tonnetti L, Eder AF, Dy B, Kennedy J, Pisciotto P, Benjamin RJ, Leiby DA,. Transfusion-transmitted Babesia microti identified through hemovigilance. Transfusion 2009; 49: 2557-63.
4. Johnson ST, Cable RG, Leiby DA,. Lookback investigations of Babesia microti-seropositive blood donors: seven-year experience in a Babesia-endemic area. Transfusion 2011.
5. Centers for Disease Control and Prevention. Interim Infection Control Guidance on 2009 H1N1 Influenza for Personnel at Blood and Plasma Collection Facilities. 2009 Nov 12.
6. Bennet J, Blajchman MA, Delage GD, Fearon M, Devine D,. Proceedings of a consensus conference: risk-based decision making for biologics evaluation. Transfus Med Rev 2011; 25: 262-92.
7. Health Canada Office of Regulatory Affairs, Biologics and Genetic Therapies Directorate. Donor exclusion to address theoretical risk of transmission of variant Creutzfeldt-Jakob disease (vCJD) through the blood supply. United Kingdom, France & Western Europe. 2001 Oct 22. [cited 2012 Jul 3]. Available from: URL: http://www.hc-sc.gc.ca/dhp-mps/brgtherap/applic- demande/guides/qualit/blood-sang/blood-vcjd-sang-vmcj-uk-ru-fr-we-eo-eng.php.
8. Health Canada, Biologics and Genetic Therapies Directorate Centre for Biologics Evaluation. Additional donor exclusion measures to address the potential risk of transmission of variant Creutzfeldt-Jakob disease (vCJD) through the blood supply. 2005 Apr 22. [cited 2012 Jul 3]. Available from: URL: http://www.hc-sc.gc.ca/dhp-mps/brgtherap/applic-demande/guides/qualit/ blood-sang/blood-vcjd-sang-vmcj-uk-ru-fr-directive-04-2005-eng.php.
9. Krever H,. Commission of Inquiry on the Blood System in Canada. 1997.
10. Health Canada. Blood donation deferral policy expanded beyond the United Kingdom and Western Europe. 2011 Mar 29. [cited 2012 Jul 3]. Available from: URL: http://www.hc-sc.gc.ca/ahc-asc/media/advisories-avis/-2011/2011-51-eng.php.
11. Hilton DA, Ghani AC, Conyers L, Edwards P, McCardle L, Ritchie D, Penney M, Hegazy D, Ironside JW,. Prevalence of lymphoreticular prion protein accumulation in UK tissue samples. J Pathol 2004; 203: 733-9.
12. Stramer SL,. Blood Products Advisory Committee Meeting. August 2, 2011. [cited 2012 Jul 3]. Available from: URL: http://www.fda.gov/downloads/ AdvisoryCommittees/CommitteesMeetingMaterials/BloodVaccinesandOtherBiologics/ BloodProductsAdvisoryCommittee/UCM265675.pdf.
13. Stramer SL,. T. cruzi incidence study in blood donors and its implications for one-time testing of blood donors, presentation of study results. 2011. p. 22-60.
14. Sanchez AM, Schreiber GB, Nass CC, Glynn S, Kessler D, Hirschler N, Fridey J, Bethel J, Murphy E, Busch MP,. The impact of male-to-male sexual experience on risk profiles of blood donors. Transfusion 2005; 45: 404-13.
15. Volkow P, Brouwer KC, Loza O, Ramos R, Lozada R, Garfein RS, Magis-Rodriguez C, Firestone-Cruz M, Strathdee SA,. Cross-border paid plasma donation among injection drug users in two Mexico-U.S. border cities. Int J Drug Policy 2009; 20: 409-12.
16. Williams AE, Thomson RA, Schreiber GB, Watanabe K, Bethel J, Lo A, Kleinman SH, Hollingsworth CG, Nemo GJ,. Estimates of infectious disease risk factors in US blood donors. Retrovirus Epidemiology Donor Study. JAMA 1997; 277: 967-72.
17. Murphy EL, Bryzman SM, Glynn SA, Ameti DI, Thomson RA, Williams AE, Nass CC, Ownby HE, Schreiber GB, Kong F, Neal KR, Nemo GJ,. Risk factors for hepatitis C virus infection in United States blood donors. NHLBI Retrovirus Epidemiology Donor Study (REDS). Hepatology 2000; 31: 756-62.
18. Custer B, Kamel H, Kiely NE, Murphy EL, Busch MP,. Associations between West Nile virus infection and symptoms reported by blood donors identified through nucleic acid test screening. Transfusion 2009; 49: 278-88.
19. Custer B,. Estimated frequency of travel to endemic areas. US FDA Blood Products Advisory Committee Meeting, August 2-3, 2011.
20. Orton SL, Stramer SL, Dodd RY,. Self-reported symptoms associated with West Nile virus infection in RNA-positive blood donors. Transfusion 2006; 46: 272-7.
21. FDA Center for Biologics Evaluation and Research, Office of Blood Research and Review. Guidance for industry: implementation of acceptable full-length donor history questionnaire and accompanying materials for use in screening donors of blood and blood components. 2010 Jun 4. [cited 2012 Jul 3]. Available from: URL: http://www.fda.gov/biologicsbloodvaccines/ guidancecomplianceregulatoryinformation/guidances/blood/ucm073445.htm
22. Leiby DA, Chung AP, Cable RG, Trouern-Trend J, McCullough J, Homer MJ, Reynolds LD, Houghton RL, Lodes MJ, Persing DH,. Relationship between tick bites and the seroprevalence of Babesia microti and Anaplasma phagocytophila (previously Ehrlichia sp.) in blood donors. Transfusion 2002; 42: 1585-91.
23. Orton SL, Stramer SL, Dodd RY, Alter MJ,. Risk factors for HCV infection among blood donors confirmed to be positive for the presence of HCV RNA and not reactive for the presence of anti-HCV. Transfusion 2004; 44: 275-81.
24. Zou S, Foster GA, Dodd RY, Petersen LR, Stramer SL,. West Nile fever characteristics among viremic persons identified through blood donor screening. J Infect Dis 2010; 202: 1354-61.
25. Stramer SL, Glynn SA, Kleinman SH, Strong DM, Caglioti S, Wright DJ, Dodd RY, Busch MP,. Detection of HIV-1 and HCV infections among antibody-negative blood donors by nucleic acid-amplification testing. N Engl J Med 2004; 351: 760-8.
26. Stramer SL, Wend U, Candotti D, Foster GA, Hollinger FB, Dodd RY, Allain JP, Gerlich W,. Nucleic acid testing to detect HBV infection in blood donors. N Engl J Med 2011; 364: 236-47.
27. Busch MP, Glynn SA, Stramer SL, Strong DM, Caglioti S, Wright DJ, Pappalardo B, Kleinman SH,. A new strategy for estimating risks of transfusion-transmitted viral infections based on rates of detection of recently infected donors. Transfusion 2005; 45: 254-64.
28. Delwart E, Slikas E, Stramer SL, Kamel H, Kessler D, Krysztof D, Tobler LH, Carrick DM, Steele W, Todd D, Wright DJ, Kleinman SH, Busch MP,; NHLBI-REDS-II Study Group. Genetic diversity of recently acquired and prevalent HIV, hepatitis B virus, and hepatitis C virus infections in US blood donors. J Infect Dis 2012; 205: 875-85.
29. Dodd RY, Notari EP, Stramer SL,. Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood donor population. Transfusion 2002; 42: 975-9.
30. Zou S, Stramer SL, Notari EP, Kuhns MC, Krysztof D, Musavi F, Fang CT, Dodd RY,. Current incidence and residual risk of hepatitis B infection among blood donors in the United States. Transfusion 2009; 49: 1609-20.
31. Zou S, Dorsey KA, Notari EP, Foster GA, Krysztof DE, Musavi F, Dodd RY, Stramer SL,. Prevalence, incidence, and residual risk of human immunodeficiency virus and hepatitis C virus infections among United States blood donors since the introduction of nucleic acid testing. Transfusion 2010; 50: 1495-504.
32. Pealer LN, Marfin AA, Petersen LR, Lanciotti RS, Page PL, Stramer SL, Stobierski MG, Signs K, Newman B, Kapoor H, Goodman JL, Chamberland ME,; West Nile Virus Transmission Investigation Team. Transmission of West Nile virus through blood transfusion in the United States in 2002. N Engl J Med 2003; 349: 1236-45.
33. Stramer SL, Fang CT, Foster GA, Wagner AG, Brodsky JP, Dodd RY,. West Nile virus among blood donors in the United States, 2003 and 2004. N Engl J Med 2005; 353: 451-9.
34. Benjamin RJ, Stramer SL, Leiby DA, Dodd RY, Fearon M, Castro E,. Trypanosoma cruzi infection in North America and Spain: evidence in support of transfusion transmission. Transfusion 2012; 52: 1913-21.
35. Bern C, Montgomery SP, Katz L, Caglioti S, Stramer SL,. Chagas disease and the US blood supply. Curr Opin Infect Dis 2008; 21: 476-82.
36. Leiby DA, Read EJ, Lenes BA, Yund AJ, Stumpf RJ, Kirchhoff LV, Dodd RY,. Seroepidemiology of Trypanosoma cruzi, etiologic agent of Chagas' disease, in US blood donors. J Infect Dis 1997; 176: 1047-52.
37. Mohammed H, Linnen JM, Munoz-Jordan JL, Tomashek K, Foster G, Broulik AS, Petersen L, Stramer SL,. Dengue virus in blood donations, Puerto Rico, 2005. Transfusion 2008; 48: 1348-54.
38. Stramer SL, Hollinger FB, Katz LM, Kleinman S, Metzel PS, Gregory KR, Dodd RY,. Emerging infectious disease agents and their potential threat to transfusion safety. Transfusion 2009; 49 Suppl 2: 1S-29S.
39. Stramer SL, Linnen JM, Carrick JM, Foster GA, Krysztof DE, Zou S, Dodd RY, Tirado-Marrero LM, Hunsperger E, Santiago GA, Muñoz-Jordan JL, Tomashek KM,. Dengue viremia in blood donors identified by RNA and detection of dengue transfusion transmission during the 2007 dengue outbreak in Puerto Rico. Transfusion 2012; 52: 1657-66.
40. Bloch EM, Herwaldt BL, Leiby DA, Shaieb A, Herron RM, Chervenak M, Reed W, Hunter R, Ryals R, Hagar W, Xayavong MV, Slemenda SB, Pieniazek NJ, Wilkins PP, Kjemtrup AM,. The third described case of transfusion-transmitted Babesia duncani. Transfusion 2012; 52: 1517-22.
41. Herwaldt BL, Linden JV, Bosserman E, Young C, Olkowska D, Wilson M,. Transfusion-associated babesiosis in the United States: a description of cases. Ann Intern Med 2011; 155: 509-19.
42. Leiby DA,. Transfusion-transmitted Babesia spp.: bull's-eye on Babesia microti. Clin Microbiol Rev 2011; 24: 14-28.
43. Dodd RY, Hackett J Jr, Linnen JM, Dorsey K, Wu Y, Zou S, Qiu X, Swanson P, Schochetman G, Gao K, Carrick JM, Krysztof DE, Stramer SL,. Xenotropic murine leukemia virus-related virus does not pose a risk to blood recipient safety. Transfusion 2012; 52: 298-306.
44. Stramer SL, Collins C, Nugent T, Wang X, Fuschino M, Heitman JW, Law J, Krysztof DE, Kiely N, Todd D, Vermeulen NM, Harrington K, Kamel H, Kelvin DJ, Busch MP, St George K, Hewlett IK, Linnen JM, Norris PJ,; NHLBI Retrovirus Epidemiology Donor Study-II (REDS-II). Sensitive detection assays for influenza RNA do not reveal viremia in US blood donors. J Infect Dis 2012; 205: 886-94.
45. US Department of Health and Human Services. Protection of human subjects, Subpart A. 2009.
46. Kleinman S, Glynn SA, Busch M, Todd D, Powell L, Pietrelli L, Nemo G, Schreiber G, Bianco C, Katz L,. The 2003 West Nile virus United States epidemic: the America's Blood Centers experience. Transfusion 2005; 45: 469-79.
47. Tobler LH, Bianco C, Glynn SA, Schreiber GB, Dille BJ, Prince HE, Lanciotti RS, Linnen JM, Gallarda J, Shyamala V, Smith D, Kleinman SH, Busch MP,; NHLBI Retrovirus Epidemiology Study (REDS). Detection of West Nile virus RNA and antibody in frozen plasma components from a voluntary market withdrawal during the 2002 peak epidemic. Transfusion 2005; 45: 480-6.